Dr. Kilgo received his medical degree and completed his residency training in neurology at the Whiddon College of Medicine, and he completed a neurology fellowship with a focus on neuroimmunology at the University of Alabama at Birmingham.
His specialty is multiple sclerosis, and he hopes to increase access to clinical trials for patients with multiple sclerosis and rare diseases like neuromyelitis optica (NMO).
Dr. Kilgo serves as the Director of the Neuroimmunology and MS Clinic, one of the only clinics recognized in the state of Alabama by the National Multiple Sclerosis Society as a Partner in MS Care. He is an active member of the American Academy of Neurology with a special interest in advocacy and public policy. He serves as principal investigator on several clinical trials as well. He has delivered abstract presentations at several national meetings in addition to serving on multiple hospital committees. He also serves as the neurology residency program director.
Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Transverse myelitis
Optic neuritis
Autoimmune encephalitis
MOG-antibody associated disease (MOGAD)
Neurosarcoidosis
Clinically Isolated Syndrome
Acute Disseminated Encephalomyelitis (ADEM)
Autoimmune and inflammatory diseases of the central nervous system
William Kilgo, M.D., applied the test to a diverse group of patients to determine the feasibility of its real-world application and concluded it is a reliable indicator of disease activity.
“I am thrilled to be able to represent residents at the national level and represent our Alabama residents at the state level,” Daniel Lee, M.D., said.
